RxDoctor Payments Data

Anand Lothe, MD

Internal Medicine · Glen Allen, VANPI 1851343180

Payments from drug & device makers

$8,581in general payments, 2019–2025

Across 573 payments — averaging $14.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$922
  • Amgen$808
  • Novo Nordisk$713
  • GSK$432
  • AstraZeneca$420
  • plus $4K from 43 others

What the payments were for

  • Food & beverage$8,544100%
  • Education$200%
  • Entertainment$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,581 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$240,538
Medicare patients
454
Services billed
4,914

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin68$106,955
XareltoRivaroxaban55$73,093
EliquisApixaban63$66,791
RybelsusSemaglutide35$46,442
JanuviaSitagliptin Phosphate15$23,056
FarxigaDapagliflozin Propanediol12$19,771
Lantus SolostarInsulin Glargine,hum.Rec.Anlog36$6,761
Atorvastatin Calcium627$5,350
Wixela InhubFluticasone Propion/Salmeterol26$4,095
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$4,076
Rosuvastatin Calcium338$3,945
SynthroidLevothyroxine Sodium73$2,672
Metoprolol Succinate150$2,213
Celecoxib36$2,140
Escitalopram Oxalate160$1,950

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$395$106,95568 claims
Johnson & JohnsonXarelto$350$73,09355 claims
PfizerEliquis$922$66,79163 claims
Novo NordiskRybelsus$713$46,44235 claims
MerckJanuvia$124$23,05615 claims
AstraZenecaFarxiga$420$19,77112 claims
AbbVieSynthroid$1,486$2,67273 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$46$1,656223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Glen Allen

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →